anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Accumulating evidence indicates that PSAT1 not only reprogrammed metabolic function but also exhibits "moonlighting" functions in promoting tumor malignancy. However, the underlying molecular mechanisms of PSAT1 promoting ER-negative breast cancer cell migration need further investigation.
METHODS: Briefly, the PSAT1 and ITGA2 expression in cells and tissues was detected using qRT-PCR, immunofluorescence staining and western blot assay. The effect of PSAT1 and ITGA2 was verified both in vitro and in vivo. RNA-seq analysis explored a series of differently expressed genes. The regulation between SP1 and ITGA2 was investigated by ChIP analysis.
RESULTS: We reported PSAT1 was highly expressed in ER-breast cancer tissues and tumor cells and positively correlated with metastasis. Moreover, RNA-seq analysis explored a series of differently expressed genes, including ITGA2, in PSAT1 overexpressed cells. Mechanistically, PSAT1 facilitated breast cancer metastasis via the p-AKT/SP1/ITGA2 axis. We further elucidated that PSAT1 promoted the entry of SP1 into the nucleus through the upregulation of p-AKT and confirmed ITGA2 is a target of SP1. In addition, enhanced cell migration was remarkably reversed by ITGA2 depletion or p-AKT inhibitor treatment.
CONCLUSION: This study clarified the mechanism of PSAT1 in promoting ER-negative breast cancer metastasis, which may provide mechanistic clues for attenuating breast cancer metastasis.
Administration of repeat doses of FACTIVE had no effect on the repeat dose pharmacokinetics of theophylline, digoxin or an ethinylestradiol/levonorgestrol oral contraceptive product in healthy subjects. (See CLINICAL PHARMACOLOGY: Drug-Drug Interactions.)

Concomitant administration of FACTIVE and calcium carbonate, cimetidine, omeprazole, or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance. (See CLINICAL PHARMACOLOGY.)

Concomitant administration of FACTIVE with probenecid resulted in a 45% increase in systemic exposure to gemifloxacin. (See CLINICAL PHARMACOLOGY.)

FACTIVE had no significant effect on the anticoagulant effect of warfarin in healthy subjects on stable warfarin therapy. However, post-marketing reports of increases in the INR, or PT, and/or clinical episodes of bleeding in patients have been noted with the use of quinolones, including FACTIVE, and warfarin, or its derivatives. In addition, infectious disease and its accompanying inflammatory process, age and general status of the patient are risk factors for increased anticoagulation activity. Therefore, the PT, INR or other suitable coagulation test should be closely monitored if a quinolone antimicrobial, including FACTIVE, is administered concomitantly with warfarin or its derivatives.

Quinolones form chelates with alkaline earth and transition metals. The absorption of oral gemifloxacin is significantly reduced by the concomitant administration of an antacid containing aluminum and magnesium. Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx® (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE. Sucralfate should not be taken within 2 hours of FACTIVE. (See CLINICAL PHARMACOLOGY.)
FIELD: medicine. SUBSTANCE: method involves applying clinical and X-ray examination of a patient and administering methotrexate at a dose of 7.5 mg per course (2.5 mg each 12 h). The patient is observed for at least one week and inflammatory process exacerbation is recorded. This witnesses in favour of Bekhterev disease diagnosis. Methotrexate response in the case of Bekhterev disease as compared with rheumatoid and psoriatic arthritis is studied, and the opposite directions of the results and statistical reliability of the differences are shown to take place. The suggested property has shown high sensitivity of 80-90% and specificity of 94%. EFFECT: enhanced effectiveness in differential diagnosis of Bekhterev disease.
OBJECTIVES: Continuous subcutaneous injection (CSCI) followed by a once-daily transdermal patch is a reasonable strategy for rapid titration of fentanyl in patients with cancer pain who are unable to take oral medication or have renal impairment, but the effectiveness and safety have not been demonstrated.
METHODS: Medical records of patients with moderate to severe cancer pain who underwent titration of fentanyl by CSCI between October 2019 and October 2021 at Kitano Hospital, Osaka, Japan, were retrospectively reviewed. The dose of fentanyl was increased to a maximum of 0.05 mg/hour. If the dose was inadequate, the fentanyl patch was added on CSCI. When pain relief was adequate, CSCI was completely converted to the patch.
RESULTS: Thirty-three patients were enrolled. Titration was completed successfully in 28 patients (85%) over a median of 2 days. The average Numeric Rating Scale for pain decreased by at least 66% in 22 patients (67%) and by at least 33% in 7 (21%). After conversion to the patch, two patients (6.1%) required to increase the dose of fentanyl within a week. Two patients (6.1%) experienced moderate drowsiness during titration.
CONCLUSIONS: Fentanyl titration by CSCI is an effective and safe method for achieving rapid pain control.
This is a single institution, open-label, baseline-controlled, prospective study evaluating the use of a non-ablative fractionated thulium laser and topical autologous platelet-rich plasma (PRP) vs. PRP injection for the treatment of male androgenetic alopecia (MAA). Given that this is a feasibility study, the investigators do provide formal sample size calculations. The findings of the study will inform that effect size associated with the treatment under study, which will inform the sample size (and power) calculations of a full, large-scale study. For this feasibility study, the investigators conservatively estimated the number of eligible patients that can reasonably enroll in the study time frame. Over the course of 1 year, the investigators typically see 50 patients with this condition annually. Of those, the investigators anticipate 25-50% would be eligible and agree to participate in the study. Given this, the investigators reasonably believe the enrollment will be 12 male subjects, ≥ 18 years of age at time of signed informed consent, of whom 6 will be randomized to receive laser + topical PRP and 6 to receive PRP injection. Follow-up visits are planned for months 7, 10, 13, and 16. Standardized photography, hair density measurement of the treated scalp areas will be recorded Pre and Post Treatment at each visit. Measurement outcomes will be compared to baseline. During the initial visit, subjects who meet the study's eligibility criteria will receive the first treatment after signing informed consent form.
Bacterial biofilms can adhere to various surfaces in the environment with human beings being no exception. Enclosed in a self-secreted matrix which contains extracellular polymeric substances, biofilms are intricate communities of bacteria that play a significant role across various sectors and raise concerns for public health, medicine and industries. These complex structures allow free-floating planktonic cells to adopt multicellular mode of growth which leads to persistent infections. This is of great concern as biofilms can withstand external attacks which include antibiotics and immune responses. A more comprehensive and innovative approach to therapy is needed in view of the increasing issue of bacterial resistance brought on by the overuse of conventional antimicrobial medications. Thus, to oppose the challenges posed by biofilm-related infections, innovative therapeutic strategies are being explored which include targeting extracellular polymeric substances, quorum sensing, and persister cells. Biofilm-responsive nanoparticles show promising results by improving drug delivery and reducing the side effects. This review comprehensively examines the factors influencing biofilm formation, host immune defence mechanisms, infections caused by biofilms, diagnostic approaches, and biofilm-targeted therapies.
This invention provides a Chinese medicine composition and a topical paste-like preparation for use in the treatment of bedsore or intractable wounds due to trauma or diseases. Namely, the present invention provides a topical Chinese medicine composition for use in the treatment of traumatic wounds or bedsores, comprising Chinese medicines such as dried ginger, Aconiti Lateralis Preparata Radix(Fu zi or baked Fu Zi), cinnamomum(Cassia cinnamon) etc. as active ingredients. The preferred formulation thereof; in addition to the above ingredients, further contains Bunge pricklyash Peel, or together with Fructus Evodiae, or additionally together with Paeoniae radix and Cortex Magnoliae Offininalis, or further together with Olibanum, Myrrha, or furthermore together with Catechu. Another preferred formulation for the topical Chinese medicine compostion further contains lyophilized mycelia extract of Flammulina velutipes in addition to the aforesaid ingredients. The topical Chinese medicine compostion according to the present invention is an ointment preparation prepared by pulverizing the Chinese medicines in the above formulation and mixing the pulverized medicines with fat (for example, lard) with stirring to form a paste.
PURPOSE:A microcapsule showing sustained release effect of drug in the stomach and the intestine, capable of releasing it securely in these digestive organs, obtained by forming an ethyl cellulose wall film on the core substance of particles which are obtained by granulating a drug substance and an enteric high polymer substance. CONSTITUTION:An enteric high polymer substance soluble in water at >=5pH is dissolved or swelled in an inert solvent to give a solution or gel, to which a drug substance suitable for oral medication is added, and the drug is dissolved or dispersed in it. The mixture is granulated, the prepared granules are dried, and the size of the granules anr adjusted to give particles having the desired particle size (preferably 50-500mu particle size). These particles are dispersed into an ethyl cellulose-containing solution, and, an ethyl cellulose wall film is formed on the core substance optionally in the presence an enteric high polymer substance by phase separation. Polysaccharide acetate, alkyl ether of carboxyalkylated polysaccharide, PVA, etc. are used as the enteric high polymer substance.
ETHNOPHARMACOLOGICAL RELEVANCE: Interstitial lung disease (ILD) is a chronic lung dysfunction disease with a poor prognosis and poor recovery. The clinically used therapeutic drugs, such as glucocorticoids and immunosuppressants, have no significant therapeutic effect and are accompanied with severe side effects. In recent years, considerable progress has been made in exploring and applying natural herb components for treating ILD. Traditional Chinese Medicine (TCM) possesses innate, non-toxic characteristics and offers advantages in preventing and treating pulmonary ailments. However, a comprehensive study of TCM on ILD therapy has not yet been reviewed.
AIM OF THE REVIEW: This review aimed to provide a comprehensive summary of the monomer components, total extracts, and prescriptions of TCM for ILD therapy, elucidating their molecular mechanisms to serve as a reference in treating ILD.
MATERIALS AND METHODS: The literature information was searched in the PubMed, Web of Science databases. The search keywords included 'interstitial lung disease', 'lung fibrosis' or 'pulmonary fibrosis', and 'traditional Chinese medicine', 'traditional herbal medicine', or 'herb medicine'.
RESULTS: The active components of single herbs, such as alkaloids, flavonoids, terpenoids, phenols, and quinones, have potential therapeutic effects on ILD. The active extracts and prescriptions were also summarized and analyzed. The herbs, Glycyrrhiza uralensis Fisch. (Gancao), Astragalus membranaceus Fisch. Bunge. (Huangqi) and Angelicasinensis (Oliv.) Diels (Danggui), play significant roles in the treatment of ILD. The mechanisms involve the inhibition of inflammatory factor release, anti-oxidative injury, and interference with collagen production, etc. CONCLUSION: This review examines the therapeutic potential of TCM for ILD and elucidates its molecular mechanisms, demonstrating that mitigating inflammation and oxidative stress, modulating the immune system, and promoting tissue repair are efficacious strategies for ILD therapy. The depth research will yield both theoretical and practical implications.
The purpose of the invention is to provide microspherical particles having an excellent massage effect. Another purpose of the invention is to provide microspherical particles that impart an excellent massage effect and cleansing effect when combined with a cleansing composition or the like. Microspherical particles are formed by powdered cellulose. The average particle size of the microspherical particles is 50-2000 μm, the sphericity is 0.7-1.0, and the dry hardness is 1-5000. Particles having a dry hardness of from 1 to less than 210 are soft-type microspherical particles, and particles having a dry hardness of 210-5000 are hard-type microspherical particles. A massage composition and cleansing composition are made by combining the microspherical particles.
1,098,877. Direction indicator switches for road vehicles. JOSEPH LUCAS (INDUSTRIES) Ltd. March 16, 1966 [March 26, 1965], No. 12876/65. Heading G4Q. A turn indicator switch comprises a rotatable actuating member 23 carrying bridging contacts 29 and 31 adapted to bridge fixed contact pairs on an insulating board 22. The member 23 is formed integrally with a pair of arms (of which one, 32b is shown in Fig. 2) each in corporating a latch portion 33b and a cam portion 34b. When the actuating member is rotated a latch portion rides up a corresponding ramp 20b until it engages a shoulder 51b of the ramp to latch the switch in the engaged position against the bias of a return spring. When the steering wheel is rotated to make the turn, a striker (49, Fig. 1, not shown) on the steering column engages the cam portion 34b and deflects the arm 32b towards the support 20; when the steering column rotates in the other direction after the turn, engagement of the striker with the cam portion 34b moves the arm 32b away from the support thereby releasing the latch and allowing the switch to return to its central position under the influence of the return spring. The latter may comprise a spring (53, Fig. 10, not shown) engaged by the opposite latch portion, or may comprise a V-shaped spring (26, Fig. 5, not shown) attached at its apex to the actuating member and having arms engaging lugs (27, 28) formed on the support 20. Headlamp switch.-The operating lever 37 is pivoted at 41 to actuating member 23 and is connected to a lever member 36 provided with slots 40 which engage one end of a plunger. The other end of the plunger carries a plate 42 engaging spring contacts (43 and 44, Fig. 4, not shown) on the board 22. In two positions of lever 37, when pivoted about the axis (41), the lever is held in the operative position by the engagement of spring-loaded balls (46, Fig. 6, not shown) in member 23 with holes in parallel surfaces of member 36. In a third operative position, a resilient finger 38 engages an arcuate projection (48, Figs. 1 and 3, not shown) thereby biassing the switch back towards the second position.
Ketogenic diet (KD) will be administered by the non-fasting protocol. The child will be admitted to the hospital, and KD will be started in 1:1 ratio. The ratio will increased every 48hours to a maximum of 4:1 or ketosis (urinary ketones 40-80mg/dL) is attained. The child will thereafter be discharged and followed up on Out patient basis.
Participants who meet all inclusion criteria and none of the exclusion criteria will be randomized to receive either acamprosate or placebo in a 1:1 ratio. Participants will be instructed to take (2) 333 mg tablets three times a day. Participants will be seen weekly for 12 weeks an again 14 weeks from randomization. At each weekly visit, participants will be asked about substance use and possible adverse events. They will also have their vital signs and weight measured at each visit. Psychiatric assessments, including the MADRS,HAM-A, Liebowitz Social Anxiety Scale, and Hospital Anxiety and Depression Scale will be performed at weeks 2, 4, 8, and 12. Alcohol craving will be assessed using the Obsessive Compulsive Drinking Scale at baseline and monthly. A urine drug screen will also be performed monthly. A clinical global impressions scale will be completed for both psychiatric and alcohol abuse symptoms at every visit. A breath alcohol test will be performed at every visit, and a urine drug screen will be performed at baseline and monthly during the trial.
The global COVID-19 pandemic has disrupted daily routines and heightened stress levels worldwide, impacting various aspects of health, including sleep. This cross-sectional study conducted in Iran aimed to investigate the impact of Ramadan Intermittent Fasting (RIF) during the pandemic on sleep disturbances and associated risk factors in adults aged ≥ 18 years. Data was collected from Iranian participants observing RIF. A structured electronic questionnaire, translated into Persian, gathered information on sociodemographics, dietary habits, sleep parameters, physical activity, and more. The study assessed sleep quality, duration, and disturbances and conducted a thorough analysis to identify risk factors associated with sleep disruptions. The study revealed that 48% of the participants experienced sleep disturbances during RIF, with 21% reporting poor sleep quality and 46% having unusual sleep duration. Various factors were associated with an elevated risk of sleep disruptions, including body mass index, place of residence, income levels, cohabitation status, family history of obesity, hypertension, diabetes, heart disease, personal history of obesity, weight fluctuations, Shisha smoking, and unemployment. The results highlight the critical importance of health promotion strategies tailored to cultural contexts. This study advocates for enhanced health education initiatives focusing on sleep hygiene and stress management, especially during periods of significant lifestyle alterations like Ramadan amid a global pandemic. Such initiatives are vital in mitigating sleep disturbances and promoting overall well-being in populations facing unique health challenges.
PURPOSE: To enhance the stability of an iodophor and control the utmost exudation of iodine from an iodophor solution through a package containing it, by introducing an additional iodide for enhancing the stability of the iodophor and controlling exudation of iodine through the package to the utmost. CONSTITUTION: A package includes an additive iodine for enhancing the stability of an organic iodophor solution and the iodophor, and controlling exudation of iodine caused through the package to the utmost. The iodophor is preferably polyvinylpyrrolidon. The package is preferably formed from a polyethylene and takes a shape of sealed plastic container. An additional iodine of preferably at least about 0.01wt.% to the iodophor solution is introduced into the package. The package contains preferably about 4.0% or less, and further, preferably about 1.5% or less additional iodide, the most preferably about 1.0% or less additional iodide to the iodophor solution.
A process for the preparation of a solid pharmaceutically particulate material by spraydrying an aqueous dispersion comprising an active substance together with a lipid material and one or more pharmaceutically acceptable carriers. The particulate material obtained by the process has suitable properties with respect to non-cohesiveness, density and particle size, which enables it to be further processed into a solid dosage form such as, e.g. tablets. By use of the process it is possible to incorporate a relatively high amount of a lipid material into a particulate material, which makes the process especially suitable for use in the preparation of pharmaceutical compositions containing a therapeutically and/or prophylactically active substance that has a relatively low aqueous solubility, has a relatively low bioavailability and/or is subject to chemical decomposition. By employment of the process according to the invention pharmaceutical compositions can be prepared that have improved physico-chemical properties e.g. with respect to release of the active substance from the composition as evidenced by in vitro dissolution test and/or improved pharmacological properties e.g. with respect to bioavailability and efficacy.
This K08 focuses on the preparation phase, which consists of compiling information from various sources, including behavioral theory, scientific literature, secondary analyses of existing data, and formative research to inform a theoretical model. This model guides intervention-related decisions, such as the selection of intervention components. Piloting of intervention components and the identification and operationalization of an optimization criterion also occur in this phase. The investigators will first use social network analyses to elucidate network characteristics that influence ALWHs' retention and adherence (Aim 1), then use participatory methods to inform intervention development (Aim 2), and lastly assess intervention acceptability, feasibility, safety and evidence of efficacy (Aim 3). Aim 3 is the clinical trial component and described in detail below. Aim 1 will determine how ALWHs' social networks influence their retention in HIV care and ART adherence and Aim 2 will then focus on the development of a network-based, social support intervention to improve ALWH retention in HIV care and ART adherence informed by Aim 1 and other relevant information.

The goal of aim 3 is to assess intervention acceptability, feasibility, safety and evidence of efficacy through open piloting. The investigators will assess intervention acceptability, feasibility, safety, and evidence of efficacy using an iterative process enabling feedback and continuing quality improvement over the course of implementation. This approach involves the piloting of the network intervention developed in Aim 2. The rationale is that the best interventions for ALWH will consider their unique needs and include tailored components. The outcome of this Aim will be a feasible and acceptable social network intervention that will be tested in an adaptive intervention using future grant funding. The hypothesis for aim 3 is that the intervention will be acceptable, feasible, and safe, with trends towards improved ALWH retention in HIV care and ART adherence.
Autophagy is a bulk degradation system that maintains cellular homeostasis by producing energy and/or recycling excess proteins. During early placentation, extravillous trophoblasts invade the decidua and uterine myometrium, facing maternal immune cells, which participate in the immune suppression of paternal and fetal antigens. Regulatory T cells will likely increase in response to a specific antigen before and during early pregnancy. Insufficient expansion of antigen-specific Treg cells, which possess the same T cell receptor, is associated with the pathophysiology of preeclampsia, suggesting sterile systemic inflammation. Autophagy is involved in reducing inflammation through the degradation of inflammasomes and in the differentiation and function of regulatory T cells. Autophagy dysregulation induces protein aggregation in trophoblasts, resulting in placental dysfunction. In this review, we discuss the role of regulatory T cells in normal pregnancies. In addition, we discuss the association between autophagy and regulatory T cells in the development of preeclampsia based on reports on the role of autophagy in autoimmune diseases.